Ovid Therapeutics Says Preclinical Data of OV101 Shows Behavioral Improvements in Fragile X Syndrome Model

Ovid Therapeutics Says Preclinical Data of OV101 Shows Behavioral Improvements in Fragile X Syndrome Model

New York-based Ovid Therapeutics (OVID) reported Monday new positive preclinical data on OV101 showing normalization of behavioral abnormalities resembling those seen in people with Fragile X syndrome. “Treatment with OV101 results in significant behavioral improvements that are consistent across all behavioral endpoints tested,” said Matthew During, chief scientific officer. “We designed this study to deepen our understanding of the mechanisms of action and potential benefit of OV101 to treat patients […]

Read More ˃
CRISPR Wins Grant to Research Friedreich’s Ataxia Treatments From Research Alliance

CRISPR Wins Grant to Research Friedreich’s Ataxia Treatments From Research Alliance

CRISPR Therapeutics (CRSP), a genome editing company that seeks to create transformative medicine for serious diseases, said on Friday it received, the Kyle Bryant Translational Research Award, from Friedreich’s Ataxia Research Alliance (FARA), a non-profit organization seeking a cure for Friedreich’s Ataxia (FA). The grant is awarded to fund research on CRISPR/Cas9-based gene-editing approaches to treat FA. The research will be performed in collaboration with Dr. Marek Napierala at the […]

Read More ˃
AcelRx Shares Plunge 51% Pre-Bell After FDA Says Cannot Approve Dsuvia Application in Present Form

AcelRx Shares Plunge 51% Pre-Bell After FDA Says Cannot Approve Dsuvia Application in Present Form

AcelRx Pharmaceuticals (ACRX) shares were down over 51% in recent pre-market trade after the company said it received a complete response letter (CRL) from the U.S. Food and Drug Administration in which the regulator said it cannot approve the new drug application (NDA) for Dsuvia in its present form. The FDA provided recommendations needed for resubmission, AcelRx said. Dsuvia is a synthetic opioid analgesic indicated for the treatment of patients […]

Read More ˃
Wall Street Steady Pre-Bell

Wall Street Steady Pre-Bell

Wall Street pre-bell Thursday is flatfooted, with U.S. stock index futures pointing to an opening bell largely unchanged from Wednesday’s close, although the Nasdaq may open slightly higher. European bourses are mixed while Asian exchanges were closed on holiday, or muted. Spain-Catalonia relations remain strained, but Spanish stocks have stabilized. Google introduced its new smartphone, named the Pixel 2, and also wireless headphones, dubbed Pixel Buds, touted as able to […]

Read More ˃